Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 科学研究和技术服务业
Company Introduction 上海泓博智源医药股份有限公司是一家快速发展的新药研发服务及原料药生产企业。自2007年12月成立以来，公司以科技创新为驱动力，以创建具有特色的“智力型”创新企业为目标，积极与客户及商业伙伴开展全方位的合作，努力成为新药创制服务和原料药工艺创新研究、生产和销售的领军企业。 泓博医药总部坐落于上海浦东新区张江高科技产业园东区，拥有约11,100平米的办公区、实验室及先进的仪器设备。公司自创立之初就着力为员工创造一个安全、舒适、科学的工作环境，目前拥有NMR(Bruker400M)、SFC、HPLC、chiral-HPLC、LC-MS、LC-MS/MS(API4000)、IR、UV、GC、GC-MS、正/反相制备色谱、微波合成仪、平行合成仪、差示扫描量热仪（DSC）、电子显微镜等各类实验及检测设备。正是这样高品质的科研环境保证了泓博医药研发部门高质量的运营及科研成果。作为高新技术企业，公司至今已获得23项国内外专利授权，其中国内授权专利22项，美国授权专利1项。 位于辽宁省开原市的泓博智源（开原）药业作为生产基地，占地面积6万平方米，拥有符合现行GMP标准的厂房、设备设施和检验系统，主要从事国际前沿的高端化学原料药及中间体的研发、生产和销售，现有产品包括替格瑞洛、帕拉米韦、维帕他韦、索菲布韦等，已经取得欧盟COS证书和多项国际高端认证。 截止到2021年12月31日，泓博医药活跃客户数达到76家，50%以上为海外客户，包括Agios,Alexion,Astellas,Astrazeneca,Cipla,Dr.Reddy,Novartis,Sanofi,Servier,SunPharma,TEVA等知名企业，具备长足发展的巨大潜力。 截止到2021年12月31日，公司有员工870人（含子公司开原泓博），其中博士/硕士约占17.7%，本科约占53.5%。2010年公司被评定为技术先进型服务企业，2014至2017年公司连续被评定为高新技术企业。陈平博士及药物化学高级副总裁蔡振伟博士均为药化资深专家，并因为对一类抗癌新药的卓越贡献，分别于2008及2011年获得美国托马斯﹒爱迪生新药发明专利奖。 泓博医药注重打造“科学为主、不断创新”的企业文化，并且将其渗透到公司的管理制度、人才培养、团队建设等各个方面。除注重科学及实验操作能力的培养之外，公司每年组织年会、素质拓展培训、团体旅游、生日会、及各种文体活动，同时还设立了团队建设专项基金。这些活动不仅为员工提供了纵向、横向的交流机会，同时增强了员工的归属感与团队合作意识。
Main Business 药物发现、制药工艺的研究开发以及原料药中间体的商业化生产
Legal Representative Ping Chen
Top Executives
董事长：PING CHEN
董事：费征,蒋胜力,安荣昌,Ping Chen
独立董事：邵春阳,尤启冬,程立
Top 5 Shareholder
Shareholder name Nature Holding Date
泓博智源（香港）医药技术有限公司限售股27.71%30/09/2024
安荣昌限售股7.67%30/09/2024
沈阳富邦投资有限责任公司流通A股6.21%30/09/2024
蒋胜力限售股5.67%30/09/2024
鼎泰海富投资管理有限公司流通A股4.94%30/09/2024
Company Secretary 蒋胜力
Solicitors 北京市嘉源律师事务所
Auditors 立信会计师事务所（特殊普通合伙）
Tel No 021-50720100
Fax No 021-50720097-266
Website www.pharmaresources.cn
Email info@pharmaresources.cn
Company Address
Register: 上海市浦东新区庆达路315号23幢
Office: 上海市浦东新区庆达路315号23幢
Listing Date 01/11/2022
Shares Capital
Shares Capital: 139,586,605
Total A Share: 139,586,605
Listed A Share: 76,860,305
Non-tradable A Share: 62,726,300
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.350
DPS(RMB)* ¥ 0.330
NBV Per Share(RMB)* ¥ 10.384
Market Capitalization(RMB) 2.073B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.